Earnings call Amgen delivered 10% revenue growth in FY2025, with 14 products surpassing $1B in sales and 13 growing double digits. EPS and operating margin expanded, supported by strong contributions ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at ...

These include potential risk to Repatha from Merck’s enlicitide pricing and ongoing uncertainty around the impact of lipoprotein (a) outcomes. Bernstein said clarity on Lp (a) is unlikely before ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol-lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...

Every 40 seconds, someone in the U.S. has a heart attack or stroke, and in most cases, it’s their first. 1 The good news? The risk for these devastating events can actually be significantly reduced by ...

We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Democrats achieved the worst ...

Monday - Friday, 6:00 - 7:00 PM ET Amgen CEO Bob Bradway told CNBC's Jim Cramer that a new trial showed his company's drug can reduce the risk of heart attack. "This trial answered questions that have ...